ArticleOncology letters2026
A prognostic senescence-related long non-coding RNA signature identifies cold and hot tumors of stomach adenocarcinoma.
Article in Oncology letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Patients with stomach adenocarcinoma (STAD) have a poor prognosis, and the efficacy of immunotherapy varies widely. The present study aimed to screen effective long non-coding RNAs (lncRNAs) as molecular targets for assessing the prognosis of STAD and guiding precision immunotherapy. A total of five key prognostic senescence-related lncRNAs (SenRLs; AL139147.1, LINC02057, AC093801.1, AL353804.2 and AC005363.2) were screened using bioinformatics methods. A novel validated prognostic risk model was constructed for STAD based on the SenRLs signature. For the training, test and entire set, the 5-year area under the curve values were 0.828, 0.703 and 0.772, respectively. A nomogram combining clinical variables and risk scores effectively predicted overall survival (OS) in patients with STAD. Clinical tissue samples were collected from patients with STAD, and quantitative PCR (qPCR) was employed to assess the tissue expression of SenRLs. The qPCR results showed that the expression of LINC02057, AL139147.1 and AC093801.1 was significantly higher in STAD tissues than in paracancerous tissues. By contrast, the expression of AC005363.2 and AL353804.2 was decreased in STAD tissues. The tissue expression profiles of these lncRNAs were consistent with the bioinformatics findings. The risk groups differed in their immune infiltrating cells, immune checkpoints and susceptibility to chemotherapeutic agents. Following clustering analysis, the two clusters had distinct tumor microenvironment profiles. Notably, based on well-established immunological characteristics, Cluster 2 was identified as representing hot tumors that are presumably more likely to benefit from immunotherapy. The newly developed SenRLs signature can serve as an independent prognostic biological marker of STAD. These SenRLs can effectively distinguish between hot and cold tumors, thereby better facilitating the screening of the beneficiary population for STAD immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.